Back to stock research

Earnings research

LLY Q1 2026

Lilly reported first-quarter 2026 results, raised full-year guidance and highlighted Mounjaro, Zepbound, orforglipron and broader pipeline progress.

Reported outcomes

Revenue
US$19.799 billion
Up 56% year over year
Reported diluted EPS
US$8.26
Up 170% year over year
Revenue volume effect
+65%
Year-over-year contribution, partly offset by a 13% lower realized-price effect

Management guidance

  • Lilly raised 2026 revenue guidance to US$82-US$85 billion and non-GAAP EPS guidance to US$35.50-US$37.00.

Market reaction

+13.17%

2026-04-29 $851.21 → 2026-05-01 $963.33

Prior trading close to first full trading-session close after the published release date

Open historical market data

Primary sources

Lilly Reports First-Quarter 2026 Financial ResultsEli Lilly and Company · earningsVerified

Fetched: 2026. 7. 11. AM 12시 0분 0초 UTC

Published: 2026. 4. 30. AM 12:00:00

Open original source
Eli Lilly Investor RelationsEli Lilly and Company · companyVerified

Fetched: 2026. 7. 11. AM 12시 0분 0초 UTC

Open original source
Form 10-Q for the Quarter Ended March 31, 2026Eli Lilly and Company · filingVerified

Fetched: 2026. 7. 11. AM 12시 0분 0초 UTC

Published: 2026. 4. 30. AM 12:00:00

Open original source
LLY editorial research profileAlphaVue Research · editorialVerified

Fetched: 2026. 7. 11. AM 12시 0분 0초 UTC